Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Approves Rituximab Biosimilar for CD20+ B-Cell Non-Hodgkin Lymphoma and CLL

July 23rd 2019

The FDA has approved PF-05280586, a biosimilar for rituximab, for the treatment of adult patients with CD20-positive B-cell non-Hodgkin lymphoma as a single agent or in combination with chemotherapy, or for patients with CD20-positive chronic lymphocytic leukemia in combination with chemotherapy.

The Future Treatment Landscape of AML

July 22nd 2019

Targeting IDH1/2 in AML

July 22nd 2019

Relapsed vs. Refractory Data for FLT3 Inhibitors in AML

July 22nd 2019

Data Supporting Quizartinib in FLT3+ R/R AML

July 22nd 2019

Targeting FLT3 in Patients with Relapsed/Refractory AML

July 22nd 2019

Recent Data on the Treatment of Older Patients With AML

July 22nd 2019

Management of Adverse Events in Older Patients With AML

July 22nd 2019

Role of Hypomethylating Agents in AML

July 22nd 2019

Treatment of AML With Myelodysplasia-Related Changes

July 22nd 2019

Role of Maintenance Therapy in AML

July 22nd 2019

Consolidation Strategies in AML

July 22nd 2019

Treatment Strategies and Patient Specific Factors in AML

July 22nd 2019

MRD Assessment and its Clinical Implications in AML

July 22nd 2019

Prognostic Significance of MRD in AML

July 22nd 2019

Therapeutic Approaches Based on Mutations in AML

July 22nd 2019

Best Practices for NGS Testing in AML

July 22nd 2019

Genetic Alterations in Acute Myeloid Leukemia

July 22nd 2019

Dr. Redner on the Potency of Gilteritinib in AML

July 19th 2019

Robert L. Redner, MD, a medical oncologist and hematologist, and professor of medicine, at the University of Pittsburgh Medical Center Hillman Cancer Center, discusses the potency of gilteritinib (Xospata) in acute myeloid leukemia (AML).

Practical Perspectives on the Diagnosis and Treatment of Hairy Cell Leukemia

July 13th 2019

Gary J. Schiller, MD, discusses the challenges with treating patients with hairy cell leukemia and some emerging therapies that could impact clinical practice.